|
1
|
Clemens MJ: Targets and mechanisms for the
regulation of translation in malignant transformation. Oncogene.
23:3180–3188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bull JH, Ellison G, Patel A, et al:
Identification of potential diagnostic markers of prostate cancer
and prostatic intraepithelial neoplasia using cDNA microarray. Br J
Cancer. 84:1512–1519. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rashid A, Pizer ES, Moga M, et al:
Elevated expression of fatty acid synthase and fatty acid synthetic
activity in colorectal neoplasia. Am J Pathol. 150:201–208.
1997.PubMed/NCBI
|
|
4
|
Gansler TS, Hardman W III, Hunt DA, et al:
Increased expression of fatty acid synthase (OA-159) in ovarian
neoplasms predicts shorter survival. Hum Pathol. 18:686–692. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gansler TS, Hardman W III, Hunt DA, et al:
Immunohistochemical expression and prognostic significance of FAS
and GLUT1 in bladder carcinoma. Anticancer Res. 23:335–339.
2003.PubMed/NCBI
|
|
6
|
Nemoto T, Terashima S, Kogure M, et al:
Overexpression of fatty acid synthase in oesophageal squamous cell
dysplasia and carcinoma. Pathobiology. 69:297–303. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kusakabe T, Nashimoto A, Honma K and
Suzuki T: Fatty acid synthase is highly expressed in carcinoma,
adenoma and in regenerative epithelium and intestinal metaplasia of
the stomach. Histopathology. 40:71–79. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Piyathilake CJ, Frost AR, Manne U, et al:
The expression of fatty acid synthase (FAS) is an early event in
the development and progression of squamous cell carcinoma of the
lung. Hum Pathol. 31:1068–1073. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pizer ES, Lax SF, Kuhajda FP, Pasternack
GR and Kurman RJ: Fatty acid synthase expression in endometrial
carcinoma: correlation with cell proliferation and hormone
receptors. Cancer. 83:528–537. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alò PL, Visca P, Marci A, Mangoni A, Botti
C and Di Tondo U: Expression of fatty acid synthase (FAS) as a
predictor of recurrence in stage I breast carcinoma patients.
Cancer. 77:474–482. 1996.PubMed/NCBI
|
|
11
|
Pizer ES, Wood FD, Heine HS, Romantsev FE,
Pasternack GR and Kuhajda FP: Inhibition of fatty acid synthase
delays disease progression in a xenograft model of ovarian cancer.
Cancer Res. 56:189–193. 1996.PubMed/NCBI
|
|
12
|
Alò PL, Visca P, Botti C, et al:
Immunohistochemical expression of human erythrocyte glucose
transporter and fatty acid synthase in infiltrating breast
carcinomas and adjacent typical/ atypical hyperplastic or normal
breast tissue. Am J Clin Pathol. 116:129–134. 2001.PubMed/NCBI
|
|
13
|
Alò PL, Visca P, Framarino ML, et al:
Immunohistochemical study of fatty acid synthase in ovarian
neoplasms. Oncol Rep. 7:1383–1388. 2000.PubMed/NCBI
|
|
14
|
Costello LC and Franklin RB: ‘Why do
tumour cells glycolyse?’: from glycolysis through citrate to
lipogenesis. Mol Cell Biochem. 280:1–8. 2005.
|
|
15
|
De Schrijver E, Brusselmans K, Heyns W,
Verhoeven G and Swinnen JV: RNA interference-mediated silencing of
the fatty acid synthase gene attenuates growth and induces
morphological changes and apoptosis of LNCaP prostate cancer cells.
Cancer Res. 63:3799–3804. 2003.PubMed/NCBI
|
|
16
|
Menendez JA, Vellon L and Lupu R:
Orlistat: From antiobesity drug to anticancer agent in Her-2/neu
(erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med
(Maywood). 230:151–154. 2005.PubMed/NCBI
|
|
17
|
Pemble CW IV, Johnson LC, Kridel SJ and
Lowther WT: Crystal structure of the thioesterase domain of human
fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol.
14:704–709. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Knowles LM, Axelrod F, Browne CD and Smith
JW: A fatty acid synthase blockade induces tumor cell-cycle arrest
by down-regulating Skp2. J Biol Chem. 279:30540–30545. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin.
58:71–96. 2008.
|
|
20
|
Raki M, Rein DT, Kanerva A and Hemminki A:
Gene transfer approaches for gynecological diseases. Mol Ther.
14:154–163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu R, Li Z, Bai S, et al: Mechanism of
cancer cell adaptation to metabolic stress: proteomics
identification of a novel thyroid hormone-mediated gastric
carcinogenic signaling pathway. Mol Cell Proteomics. 8:70–85. 2009.
View Article : Google Scholar
|
|
22
|
Tong A, Wu L, Lin Q, et al: Proteomics
analysis of cellular protein alterations using a hepatitis B
virus-producing cellular model. Proteomics. 8:2012–2023. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu R, Wang K, Yuan K, et al: Integrative
oncoproteomics strategies for anticancer drug discovery. Expert Rev
Proteomics. 7:411–429. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Medes G, Thomas A and Weinhouse S:
Metabolism of neoplastic tissue. IV: A study of lipid synthesis in
neoplastic tissue slices in vitro. Cancer Res. 13:27–29.
1953.PubMed/NCBI
|
|
25
|
Witkowski A, Joshi AK and Smith S:
Coupling of the de novo fatty acid biosynthesis and lipoylation
pathways in mammalian mitochondria. J Biol Chem. 282:14178–14185.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chirala SS and Wakil SJ: Structure and
function of animal fatty acid synthase. Lipids. 39:1045–1053. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kuhajda FP, Jenner K, Wood FD, Hennigar
RA, Jacobs LB, Dick JD and Pasternack GR: Fatty acid synthesis: a
potential selective target for antineoplastic therapy. Proc Natl
Acad Sci USA. 91:6379–6383. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Christofk HR, Vander Heiden MG, Harris MH,
et al: The M2 splice isoform of pyruvate kinase is important for
cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guminska M, Ignacak J, Kedryna T and
Stachurska MB: Tumor-specific pyruvate kinase isoenzyme M2 involved
in biochemical strategy of energy generation in neoplastic cells.
Acta Biochim Pol. 44:711–724. 1997.PubMed/NCBI
|
|
30
|
Mazurek S, Boschek CB, Hugo F and
Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth
and spreading. Semin Cancer Biol. 15:300–308. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dombrauckas JD, Santarsiero BD and Mesecar
AD: Structural basis for tumor pyruvate kinase M2 allosteric
regulation and catalysis. Biochemistry. 44:9417–9429. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Spoden GA, Mazurek S, Morandell D, et al:
Isotype-specific inhibitors of the glycolytic key regulator
pyruvate kinase subtype M2 moderately decelerate tumor cell
proliferation. Int J Cancer. 123:312–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Steták A, Veress R, Ovádi J, Csermely P,
Kéri G and Ullrich A: Nuclear translocation of the tumor marker
pyruvate kinase M2 induces programmed cell death. Cancer Res.
67:1602–1608. 2007.PubMed/NCBI
|
|
34
|
Janke J, Schlüter K, Jandrig B, et al:
Suppression of tumorigenicity in breast cancer cells by the
microfilament protein profilin 1. J Exp Med. 191:1675–1686. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu N, Zhang W, Yang Y, et al: Profilin 1
obtained by proteomic analysis in all-trans retinoic acid-treated
hepatocarcinoma cell lines is involved in inhibition of cell
proliferation and migration. Proteomics. 6:6095–6106. 2006.
View Article : Google Scholar : PubMed/NCBI
|
